Developer docs
API playgroundTry for free, no card

Search company profiles

Renerva

Full company profile

uuid0003nal

Namestring
Renerva
Legal namestring
Renerva, Inc.
Websiteurl
renerva.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Renerva, Inc. is a privately held medical device company founded in 2017 as a spin-off from the University of Pittsburgh Swanson School of Engineering and Cornell University, headquartered in Pittsburgh, Pennsylvania. The company is developing a portfolio of implantable peripheral nerve repair technologies built on a proprietary platform using decellularized porcine nerve tissue and its resulting extracellular matrix. Its lead product, the Renerva PNM-CAP™, is a bioabsorbable nerve capping device with an internal neuroinhibitory 3D matrix designed to prevent neuroma formation and chronic neuropathic pain following amputation; the device received FDA Investigational Device Exemption (IDE) approval in December 2025 and completed first-in-human implantation at The Ohio State University Wexner Medical Center in May 2026.

The underlying platform supports three additional pipeline products: PNM (an injectable Peripheral Nerve Matrix Hydrogel for nerve regeneration), PNM-G (a nerve conduit for bridging nerve gap injuries), and SND (a sutureless neurorrhaphy device for primary nerve repair). Preclinical evidence demonstrates up to 17-fold reduction in nerve growth and 3.5-fold reduction in evoked pain versus standard-of-care controls, and the device remodels into healthy host-derived tissue over time. The intended end users are orthopedic, plastic, neuro, and vascular surgeons performing amputations and nerve repairs at hospitals and surgical centers, addressing a U.S. population of more than two million amputees and approximately 500,000 new extremity amputations annually, of which up to 48% develop painful neuromas.

Renerva is pre-revenue: all products are investigational and not commercially available, and the company generates no product sales today. Its business model upon commercialization is expected to be direct sales of PNM-CAP™ and pipeline devices to hospitals and surgical centers via enterprise procurement channels, with a gtm focused on positioning PNM-CAP™ as the standard of care for neuroma prevention in amputations. The company has raised approximately $10 million cumulatively since 2017 from a mix of federal grants (NSF, NIH, MTEC, U.S. Department of Defense) and angel investors (Keiretsu Forum, Cowtown Angels, Rochester Angel Network, Chemical Angel Network), and operates with a lean 1–10 person team.

Short descriptiontext

Renerva is a pre-revenue medical device company developing implantable peripheral nerve repair products based on decellularized porcine nerve tissue, led by the PNM-CAP™ nerve cap for neuroma prevention in amputees, targeting surgeons and hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPittsburgh, United States
HQ citystring
Pittsburgh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, nerve capping devices, neuroma prevention, decellularized nerve matrix, surgical nerve implants
Industry3 codes
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Peripheral Nerve Repair Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Pre-revenue company developing implantable medical devices. Revenue will be generated through sales of PNM-CAP™ nerve cap devices and other pipeline products (PNM hydrogel, PNM-G graft, SND device) to hospitals and surgical centers upon FDA approval and commercialization.

renerva.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Renerva PNM-CAP™
Description

A bioabsorbable nerve capping device made of porcine nerve extracellular matrix designed to prevent neuroma formation and chronic nerve pain. It features a neuro-inhibitory 3D matrix that prevents nerve growth and entanglement.

renerva.com
+3 more records
Core offering1 text field

Renerva develops and is advancing toward commercialization a portfolio of implantable peripheral nerve repair medical devices built on a proprietary decellularized porcine nerve extracellular matrix platform. Its lead product, the Renerva PNM-CAP™ nerve capping device, is a bioabsorbable implant designed to prevent neuroma formation and chronic neuropathic pain following amputation, with pipeline extensions in injectable nerve regeneration hydrogel, nerve gap conduits, and sutureless nerve repair devices. All products are investigational and not yet commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 17-fold reduction in nerve growth compared to standard of care controls
+4 more records
Product overview1 text field

Renerva is a medical device company developing a portfolio of implantable peripheral nerve repair technologies based on decellularized porcine nerve tissue. The core product is the Renerva PNM-CAP™ nerve capping device, which received FDA IDE approval and completed first-in-human implantation. The pipeline includes PNM (Peripheral Nerve Matrix Hydrogel) for injectable nerve regeneration, PNM-G (Peripheral Nerve Matrix Graft) as a nerve conduit for gap injuries, and SND (Sutureless Neurorrhaphy Device) for primary nerve repair. All products are investigational and not yet commercially available.

Product and service4 records
1Renerva PNM-CAP™ Nerve Cap Device
CategoryNerve Capping Device / Neuroma Prevention
Description

A fully developed, packaged, and terminally sterilized bioabsorbable nerve capping device made of porcine nerve extracellular matrix, designed with a socket to entubulate the nerve end and a handling/anchoring tab for simple implantation. Features a proprietary internal neuroinhibitory 3D matrix that prevents nerve growth and entanglement for effective, long-term inhibition of neuroma and neuropathic pain. Available in multiple sizes for the prevention or treatment of neuroma in amputees. For use by orthopedic, plastic, neurosurgical, and vascular surgeons and their hospitals.

2PNM Peripheral Nerve Matrix Hydrogel
CategoryInjectable Nerve Regeneration Hydrogel
Description

Injectable gel derived from decellularized porcine nerve extracellular matrix designed to improve nerve growth and functional recovery following nerve injury by providing a neuroinductive interface between nerve and muscle. Pipeline product intended for surgeons treating peripheral nerve injuries.

3PNM-G Peripheral Nerve Matrix Graft
CategoryNerve Conduit / Nerve Gap Repair
Description

Nerve conduit designed to bridge nerve gap injuries, using decellularized porcine nerve-derived hydrogel as a filler to improve electrophysiologic response and axon counts. Pipeline product for trauma and reconstructive surgeons treating peripheral nerve gap injuries.

4SND Sutureless Neurorrhaphy Device
CategorySutureless Nerve Repair Device
Description

Device designed to obtain atraumatic primary nerve repair, enabling sutureless connection of severed nerve ends. Pipeline product for surgeons performing peripheral nerve repair procedures.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Renerva was founded out of the University of Pittsburgh Swanson School of Engineering in 2017. Key founders Bryan Brown and Lorenzo Soletti are researchers at Pitt. The company operates in partnership with Pitt's research ecosystem.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Renerva was co-founded out of Cornell University in addition to University of Pittsburgh. The company has a satellite location in Ithaca, NY (Cornell's location) and maintains affiliation with Cornell's Life Science Ventures.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial site for first-in-human implantation of Renerva PNM-CAP™ device. Dr. Amy M. Moore serves on Renerva's Medical and Scientific Advisory Board and is Interim Dean at Ohio State's College of Medicine.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading pure-play peripheral nerve repair company (Avance nerve graft, AcroVal, Axoguard) selling directly to hand and microsurgeons. Most direct US peer to Renerva's nerve cap and graft platform.

TypeDirect peer
Description

Netherlands-based developer of bioresorbable medical devices including Neurocap for neuroma prevention and nerve conduit/graft products — a close technological and indication overlap with Renerva's PNM-CAP.

TypeBroad incumbent
Description

Large diversified MedTech with NeuraGen nerve guide and broader regenerative tissue portfolio. Competes in peripheral nerve repair and has the commercial scale Renerva lacks.

TypeBroad incumbent
Description

Global MedTech incumbent with orthopedic and surgical implant portfolios covering extremities and trauma. Represents a likely strategic acquirer in the peripheral nerve / regenerative medicine space.

TypeDirect peer
Description

US company developing nerve stimulation, identification, and repair tools for surgeons, including nerve protection and repair adjuncts. Comparable customer base of hand, plastic, and orthopedic surgeons.

TypeEmerging player
Description

Emerging company developing hydrogel-based nerve and tendon protection devices (e.g., Nerve Tape) that compete at the soft-tissue nerve interface during surgical procedures.

TypeRegional player
Description

Developer of neurostimulation devices (e.g., diaphragm pacing) with adjacent peripheral nerve technology expertise. Useful analog for nerve-interface device development and FDA pathways.

8Collagen Solutions
TypeOthers
Description

Supplier of medical-grade collagen and tissue-based biomaterials used in nerve and wound repair applications — adjacent ecosystem participant and potential supplier to Renerva's pipeline.

TypeEmerging player
Description

Emerging regenerative medicine company with proprietary electrospun matrices for soft tissue repair, an architectural and commercial analog in the regenerative implant space.

TypeEmerging player
Description

Pre-commercial developer of autologous nerve tissue treatments targeting neuroma and phantom limb pain — same primary indication as Renerva's PNM-CAP.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Renerva

Peripheral Nerve Repair Medical Devicesrenerva.com

Renerva is a pre-revenue medical device company developing implantable peripheral nerve repair products based on decellularized porcine nerve tissue, led by the PNM-CAP™ nerve cap for neuroma prevention in amputees, targeting surgeons and hospitals.

What Renerva does

Renerva, Inc. is a privately held medical device company founded in 2017 as a spin-off from the University of Pittsburgh Swanson School of Engineering and Cornell University, headquartered in Pittsburgh, Pennsylvania. The company is developing a portfolio of implantable peripheral nerve repair technologies built on a proprietary platform using decellularized porcine nerve tissue and its resulting extracellular matrix. Its lead product, the Renerva PNM-CAP™, is a bioabsorbable nerve capping device with an internal neuroinhibitory 3D matrix designed to prevent neuroma formation and chronic neuropathic pain following amputation; the device received FDA Investigational Device Exemption (IDE) approval in December 2025 and completed first-in-human implantation at The Ohio State University Wexner Medical Center in May 2026.

The underlying platform supports three additional pipeline products: PNM (an injectable Peripheral Nerve Matrix Hydrogel for nerve regeneration), PNM-G (a nerve conduit for bridging nerve gap injuries), and SND (a sutureless neurorrhaphy device for primary nerve repair). Preclinical evidence demonstrates up to 17-fold reduction in nerve growth and 3.5-fold reduction in evoked pain versus standard-of-care controls, and the device remodels into healthy host-derived tissue over time. The intended end users are orthopedic, plastic, neuro, and vascular surgeons performing amputations and nerve repairs at hospitals and surgical centers, addressing a U.S. population of more than two million amputees and approximately 500,000 new extremity amputations annually, of which up to 48% develop painful neuromas.

Renerva is pre-revenue: all products are investigational and not commercially available, and the company generates no product sales today. Its business model upon commercialization is expected to be direct sales of PNM-CAP™ and pipeline devices to hospitals and surgical centers via enterprise procurement channels, with a gtm focused on positioning PNM-CAP™ as the standard of care for neuroma prevention in amputations. The company has raised approximately $10 million cumulatively since 2017 from a mix of federal grants (NSF, NIH, MTEC, U.S. Department of Defense) and angel investors (Keiretsu Forum, Cowtown Angels, Rochester Angel Network, Chemical Angel Network), and operates with a lean 1–10 person team.

Renerva firmographics

Firmographics
Name
Renerva
Legal name
Renerva, Inc.
Website
https://renerva.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Renerva is a pre-revenue medical device company developing implantable peripheral nerve repair products based on decellularized porcine nerve tissue, led by the PNM-CAP™ nerve cap for neuroma prevention in amputees, targeting surgeons and hospitals.
Ownership category
akta.pro rank

Renerva industry classification

Industry
Product category
Peripheral Nerve Repair Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Peripheral nerve repair
  • Nerve capping devices
  • Neuroma prevention
  • Decellularized nerve matrix
  • Surgical nerve implants

Where Renerva is headquartered

Location

Headquarters

HQ city
Pittsburgh
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Renerva business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Pre-revenue company developing implantable medical devices. Revenue will be generated through sales of PNM-CAP™ nerve cap devices and other pipeline products (PNM hydrogel, PNM-G graft, SND device) to hospitals and surgical centers upon FDA approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Renerva product offering

Product offering

Core offering

Renerva develops and is advancing toward commercialization a portfolio of implantable peripheral nerve repair medical devices built on a proprietary decellularized porcine nerve extracellular matrix platform. Its lead product, the Renerva PNM-CAP™ nerve capping device, is a bioabsorbable implant designed to prevent neuroma formation and chronic neuropathic pain following amputation, with pipeline extensions in injectable nerve regeneration hydrogel, nerve gap conduits, and sutureless nerve repair devices. All products are investigational and not yet commercially available.

Product overview

Renerva is a medical device company developing a portfolio of implantable peripheral nerve repair technologies based on decellularized porcine nerve tissue. The core product is the Renerva PNM-CAP™ nerve capping device, which received FDA IDE approval and completed first-in-human implantation. The pipeline includes PNM (Peripheral Nerve Matrix Hydrogel) for injectable nerve regeneration, PNM-G (Peripheral Nerve Matrix Graft) as a nerve conduit for gap injuries, and SND (Sutureless Neurorrhaphy Device) for primary nerve repair. All products are investigational and not yet commercially available.

Differentiator

Problem solved

Functional benefit

Brands

  • Renerva PNM-CAP™: A bioabsorbable nerve capping device made of porcine nerve extracellular matrix designed to prevent neuroma formation and chronic nerve pain. It features a neuro-inhibitory 3D matrix that prevents nerve growth and entanglement.
  • PNM (Peripheral Nerve Matrix Hydrogel)
  • PNM-G (Peripheral Nerve Matrix Graft)
  • SND (Sutureless Neurorrhaphy Device)

Products and services

  • Renerva PNM-CAP™ Nerve Cap Device A fully developed, packaged, and terminally sterilized bioabsorbable nerve capping device made of porcine nerve extracellular matrix, designed with a socket to entubulate the nerve end and a handling/anchoring tab for simple implantation. Features a proprietary internal neuroinhibitory 3D matrix that prevents nerve growth and entanglement for effective, long-term inhibition of neuroma and neuropathic pain. Available in multiple sizes for the prevention or treatment of neuroma in amputees. For use by orthopedic, plastic, neurosurgical, and vascular surgeons and their hospitals.
  • PNM Peripheral Nerve Matrix Hydrogel Injectable gel derived from decellularized porcine nerve extracellular matrix designed to improve nerve growth and functional recovery following nerve injury by providing a neuroinductive interface between nerve and muscle. Pipeline product intended for surgeons treating peripheral nerve injuries.
  • PNM-G Peripheral Nerve Matrix Graft Nerve conduit designed to bridge nerve gap injuries, using decellularized porcine nerve-derived hydrogel as a filler to improve electrophysiologic response and axon counts. Pipeline product for trauma and reconstructive surgeons treating peripheral nerve gap injuries.
  • SND Sutureless Neurorrhaphy Device Device designed to obtain atraumatic primary nerve repair, enabling sutureless connection of severed nerve ends. Pipeline product for surgeons performing peripheral nerve repair procedures.

Quantifiable outcome

  • Up to 17-fold reduction in nerve growth compared to standard of care controls
  • +4 more outcomes

Companies that use Renerva

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Renerva technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Renerva partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • University of PittsburghcoreStrategic or Co-development PartnerRenerva was founded out of the University of Pittsburgh Swanson School of Engineering in 2017. Key founders Bryan Brown and Lorenzo Soletti are researchers at Pitt. The company operates in partnership with Pitt's research ecosystem.
  • Cornell UniversitycoreStrategic or Co-development PartnerRenerva was co-founded out of Cornell University in addition to University of Pittsburgh. The company has a satellite location in Ithaca, NY (Cornell's location) and maintains affiliation with Cornell's Life Science Ventures.
  • The Ohio State University Wexner Medical CentercoreStrategic or Co-development PartnerClinical trial site for first-in-human implantation of Renerva PNM-CAP™ device. Dr. Amy M. Moore serves on Renerva's Medical and Scientific Advisory Board and is Interim Dean at Ohio State's College of Medicine.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Renerva competitors and assessment

Company assessment

Direct peers

  • Axogen: Leading pure-play peripheral nerve repair company (Avance nerve graft, AcroVal, Axoguard) selling directly to hand and microsurgeons. Most direct US peer to Renerva's nerve cap and graft platform.
  • Polyganics: Netherlands-based developer of bioresorbable medical devices including Neurocap for neuroma prevention and nerve conduit/graft products — a close technological and indication overlap with Renerva's PNM-CAP.
  • Checkpoint Surgical: US company developing nerve stimulation, identification, and repair tools for surgeons, including nerve protection and repair adjuncts. Comparable customer base of hand, plastic, and orthopedic surgeons.

Broad incumbents

  • Integra LifeSciences: Large diversified MedTech with NeuraGen nerve guide and broader regenerative tissue portfolio. Competes in peripheral nerve repair and has the commercial scale Renerva lacks.
  • Stryker: Global MedTech incumbent with orthopedic and surgical implant portfolios covering extremities and trauma. Represents a likely strategic acquirer in the peripheral nerve / regenerative medicine space.

Emerging players

  • Alafair Biosciences: Emerging company developing hydrogel-based nerve and tendon protection devices (e.g., Nerve Tape) that compete at the soft-tissue nerve interface during surgical procedures.
  • Acera Surgical: Emerging regenerative medicine company with proprietary electrospun matrices for soft tissue repair, an architectural and commercial analog in the regenerative implant space.
  • Tulavi Therapeutics: Pre-commercial developer of autologous nerve tissue treatments targeting neuroma and phantom limb pain — same primary indication as Renerva's PNM-CAP.

Regional players

  • Synapse Biomedical: Developer of neurostimulation devices (e.g., diaphragm pacing) with adjacent peripheral nerve technology expertise. Useful analog for nerve-interface device development and FDA pathways.

Others

  • Collagen Solutions: Supplier of medical-grade collagen and tissue-based biomaterials used in nerve and wound repair applications — adjacent ecosystem participant and potential supplier to Renerva's pipeline.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Renerva social profiles

Digital presence

Renerva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Renerva leadership team

Management profile

Number of profiles

Profiles13 records

Renerva funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Renerva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Renerva

What does Renerva do?

Renerva develops and is advancing toward commercialization a portfolio of implantable peripheral nerve repair medical devices built on a proprietary decellularized porcine nerve extracellular matrix platform. Its lead product, the Renerva PNM-CAP™ nerve capping device, is a bioabsorbable implant designed to prevent neuroma formation and chronic neuropathic pain following amputation, with pipeline extensions in injectable nerve regeneration hydrogel, nerve gap conduits, and sutureless nerve repair devices. All products are investigational and not yet commercially available.

Is Renerva a public or private company?

Renerva is a private company. It is classified as venture growth investor backed and is currently operating.

When was Renerva founded?

Renerva was founded in 2017. It employs 1 to 10 people.

Where is Renerva based?

Renerva is headquartered in Pittsburgh, United States, in the North America region.

How does Renerva make money?

One revenue line is on record: medical Device Sales.

Who are Renerva's main competitors?

Direct peers on record are Axogen, Polyganics and Checkpoint Surgical. Broad incumbents are Integra LifeSciences and Stryker. Emerging players are Alafair Biosciences, Acera Surgical and Tulavi Therapeutics. Synapse Biomedical is listed as a regional player. Collagen Solutions is listed as an others.

Does Renerva have an API?

No public API is recorded for Renerva.

What industry is Renerva in?

Renerva's product category is Peripheral Nerve Repair Medical Devices. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Cornell ChronicleFive startups graduate from Cornell incubatorsFive startups—Geegah, Inso Bio, OWiC Technologies, Renerva, and Revora Materials—graduated from Cornell's incubators on Nov. 2, having raised $26 million and created 30 high-tech jobs. The companies focus on biotechnology, medical devices, and critical mineral recovery. The event also marked the retirement of Praxis Center director Bob Scharf.utimesRenerva Inc. approved for first-in-human FDA clinical trialsRenerva Inc. has received FDA Investigational Device Exemption approval to initiate the first-in-human clinical trials for its PNM-CAP device, which aims to prevent painful neuroma formation in amputees. The company plans to test the implantable nerve cap on 10 patients over one year to evaluate its ability to reduce chronic pain and opioid use.utimesPitt-Founded Startup Achieves First-in-Human Implant of Nerve Pain DeviceRenerva, Inc., a medical device startup founded by University of Pittsburgh Swanson School of Engineering researchers, has completed the first human implantation of its Renerva PNM-CAP™ device at The Ohio State University Wexner Medical Center as part of an FDA-approved clinical study. The device is designed to prevent neuroma formation, a painful nerve growth condition that affects over two million Americans living with limb loss and is a driver of chronic pain and opioid dependence. The company moved from FDA Investigational Device Exemption approval to first-in-human implantation in just a few months, representing a major milestone toward commercialization.PR NewswireRenerva Achieves First-in-Human Implant of PNM-CAP™ Device for Neuroma PainRenerva implanted the first patient with its PNM-CAP nerve capping device at The Ohio State University Wexner Medical Center. The device aims to prevent neuroma pain in amputees, with primary endpoints on pain reduction, opioid use, and quality of life. The company expects FDA clearance and commercial launch in the near term.Pittsburgh Post-GazettePitt startup gets FDA approval for trial aimed at helping amputeesRenerva Inc., a startup founded in 2017 at the University of Pittsburgh, has received an Investigational Device Exemption from the FDA to conduct a pilot study implanting biodegradable nerve caps in 10 patients to evaluate pain reduction, quality of life changes, and other metrics over one year. The nerve caps, made from specially treated porcine tissue, showed in rodent trials that pain can be reduced by an average 3.5-fold and nerve growth reduced by 16-fold compared to standard treatment, targeting painful neuromas that form at severed nerve ends following amputations. The company, which has raised about $10 million since founding, is seeking to position its product as a gold standard for preventing neuromas in future amputations, with a potential U.S. market estimated at $2 billion.PR NewswireRenerva Receives FDA IDE Approval to Commence First-in-Human Study of its Renerva PNM-CAP™ Device for Neuroma PainRenerva, Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate a first-in-human clinical study for its Renerva PNM-CAP™ device. The study will be conducted at The Ohio State University Wexner Medical Center to assess the device's ability to prevent neuroma-related chronic pain and reduce opioid use among amputees. This approval marks Renerva's transition into a clinical-stage company as it seeks US market clearance based on upcoming interim data.SecSEC FORM DRenerva, Inc., a Delaware-registered health care company headquartered in Pittsburgh, Pennsylvania, filed a Form D notice with the SEC for an exempt offering of securities under Rule 506(b), with a total offering amount of $1,500,000. The filing indicates $324,820 has already been sold to 35 investors as of September 15, 2025, leaving $1,175,180 remaining to be sold, with $53,000 of proceeds designated for payments to executive officers.NSFNSF Award SearchThe National Science Foundation awarded Renerva, Inc. a cooperative agreement valued at over $1.3 million to date for the development of a novel peripheral nerve matrix platform. The SBIR Phase II project aims to create a tissue-like nerve graft and cap derived from decellularized porcine tissue to improve clinical outcomes for patients with severe acute peripheral nerve injuries. The initiative includes conducting in-vivo studies and preparing supply chain and packaging infrastructure for a commercial launch.Cornell ChronicleNerve-healing startup Renerva joins McGovern incubatorRenerva, a medical startup developing injectable nerve-healing technologies, has joined Cornell’s McGovern Center life sciences business incubator. The company received $2.9 million in funding from the U.S. Department of Defense and other agencies to support its preclinical program and product development. Renerva's first product, Peripheral Nerve Matrix, is expected to enter clinical trials this year.utimesRenerva® Receives Funding to Expand Its Peripheral Nerve Repair TechnologiesRenerva, LLC received $500,000 in additional grants from the National Science Foundation and the National Institutes of Health to accelerate the development of its peripheral nerve repair technologies. The funding will support the expansion of its Renerva Peripheral Nerve Matrix product into new applications and the development of a novel graft for nerve gap injuries. This brings the company's total non-dilutive federal funding to $3 million as it prepares for clinical trials.